Loading, Please Wait...
SAN FRANCISCO, March 19, 2019 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., a private company discovering drugs that harness the body’s natural process to control protein levels, today announced an upcoming oral presentation at the 2019 American Association for Cancer Research (AACR) Annual Meeting from March 29 - April 3, 2019 at the Georgia World Conference Center in Atlanta, Georgia.
|Oral Presentation Details:|
|Title:||Genetic and pharmacologic evaluation of the ubiquitin ligase CBL-B as a small-molecule, tumor immunotherapy target|
|Session Category:||Experimental and Molecular Therapeutics|
|Session Title:||Preclinical Drug Development|
|Date:||Monday, April 1, 2019|
|Time:||3:50 p.m.-4:05 p.m. EDT|
|Location:||Georgia World Conference Center, Room B206|
About Nurix Therapeutics
Nurix discovers drugs that harness the body’s natural process to control protein levels. Our drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases. Our initial focus is on developing drugs as treatments for hematologic cancers and immune-mediated diseases including immuno-oncology therapeutics for cancer. Nurix was founded by internationally-recognized experts in ligase biology and immunology and is funded by leading life science investors Third Rock Ventures and The Column Group. In September 2015, Nurix and Celgene entered into a broad collaboration targeting protein homeostasis for next-generation therapies in oncology, inflammation and immunology. The company is headquartered in San Francisco, California. For more information, please visit http://www.nurix-inc.com.
LifeSci Public Relations